Understanding the Market | AB&B BIO-TECH-B rose over 8% as its quadrivalent influenza virus subunit vaccine was selected for the preliminary review list of commercial insurance, significantly highlighting its market scarcity

AB&B BIO-TECH-B's stock price rose by more than 8%, with an increase of 7.49% as of the time of publication, trading at HKD 51.25, with a transaction volume of HKD 18.463 million. The company's board of directors announced that its quadrivalent influenza virus subunit vaccine for the 6-35 month age group has been approved by the National Medical Products Administration, becoming China's first quadrivalent influenza vaccine for the entire population at full dosage. This vaccine has undergone significant upgrades based on traditional split vaccines, offering advantages such as high purity and low risk of adverse reactions, and has been included in the preliminary review list for commercial insurance, indicating significant market scarcity